Investors | Orion

Interim Report 1-9/2018

24 Oct 2018 I The release and presentation materials are now available.

Stock Exchange Releases

10/30/2018	Composition of the Nomination Committee of Orion Corporation
10/24/2018	Orion Group Interim Report January-September 2018
10/24/2018	Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met
9/19/2018	Changes in responsibility areas of the Orion Group Executive Management Board

Orion and Bayer have completed the phase III trial of darolutamide - The primary endpoint was met

Press Releases

11/1/2018	Orion Research Foundation grants million euros for research in 2019
10/24/2018	Orion and Amgen to collaborate on the commercialisation of AMGEVITA® (biosimilar adalimumab) in Finland
10/10/2018	Publishing of Orion Corporation's Interim Report for January-September 2018 on 24 October 2018
9/17/2018	Creation of novel medicines and better patient care for the future in an ecosystem

Orion has completed the sale of Orion Diagnostica business division

The Closing of the transaction took place on 30 April 2018.

Orion's R&D Pipeline

Orion's key research projects include three ongoing Phase III trials, among others.

Research

Major shareholders by votes

Monthly updated list of Orion's major shareholders by votes.

AGM 2018

The 2018 Annual General Meeting of Orion was held on Tuesday, 20 March 2018 in Helsinki.

Share information

Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.

Corporate Governance Statement

The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.

Orion Executive Management Board

The members of the Board of Directors

Annual Reports

Orion included in FTSE4Good Index

Orion Corporation has been included in the globally recognised FTSE4Good Index.